<DOC>
	<DOC>NCT01629212</DOC>
	<brief_summary>The purpose of this study was to compare the Efficacy and Safety of Tiropramide HCl and Octylonium bromide in the Treatment of Irritable Bowel Syndrome.</brief_summary>
	<brief_title>Comparison of the Efficacy and Safety of Tiropramide and Octylonium in the Treatment of Irritable Bowel Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Tiropramide</mesh_term>
	<mesh_term>Octylonium</mesh_term>
	<criteria>1. Adult patients (aged 2075 years) 2. Patients who had been suffered from IBS as defined by Rome III criteria 3. Patients who had abdominal pain at least 2 days/week, during the runin period of 2 weeks 1. Patients with known intolerance to tiropramide or octylonium 2. Patients with uncontrolled diabetes, uncontrolled hypertension or thyroid dysfunction 3. Patients who had the history of cancer [However, patients with cancer other than gastrointerstinal cancer, who have not recurr within 5 years after treatment were possible for enrollment] 4. Patients with hepatic or renal dysfunction 5. Patients with lactose intorelance</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>